RxDoctor Payments Data

Robert Esper, DO

Family Medicine · Erie, PANPI 1790767457

Payments from drug & device makers

$9,967in general payments, 2019–2025

Across 641 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Pfizer$1K
  • Novo Nordisk$778
  • AstraZeneca$657
  • GSK$640
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$9,959100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,967 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,834
Medicare patients
107
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$62,156
EliquisApixaban66$60,966
TrulicityDulaglutide40$58,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$51,003
JardianceEmpagliflozin44$47,623
MounjaroTirzepatide38$38,913
XareltoRivaroxaban36$35,978
TradjentaLinagliptin28$28,002
MyrbetriqMirabegron23$18,920
Repatha SureclickEvolocumab11$17,547
FarxigaDapagliflozin Propanediol12$12,700
Breo ElliptaFluticasone/Vilanterol12$10,719
EntrestoSacubitril/Valsartan13$9,101
VascepaIcosapent Ethyl14$7,717
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,109$97,78378 claims
Boehringer IngelheimJardiance, Tradjenta$1,106$75,62572 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$640$65,64273 claims
Novo NordiskOzempic$778$62,15649 claims
PfizerEliquis$1,099$60,96666 claims
Johnson & JohnsonXarelto$588$35,97836 claims
Astellas Pharma US IncMyrbetriq$545$18,92023 claims
AstraZenecaFarxiga$657$12,70012 claims
NovartisEntresto$122$9,10113 claims
AbbVieSynthroid$575$1,18717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →